SHESPEAKS Your Power to Influence



Welcome to the SheSpeaks #beBRCAware Program. Thank you for joining us to raise awareness of the BRCA gene and the role it plays in ovarian cancer. We look forward to reading your blog post!

How to Participate in the Program

Important Campaign Links
Hashtag: #beBRCAware
Website: myocjourney.com
Twitter: @beBRCAware
Facebook: https://www.facebook.com/pages/beBRCAware/250939935114040
YouTube: https://www.youtube.com/channel/UCmqqk6o8esolywblpF4-IKQ

Key Messages & Calls to Action for Your #beBRCAware Blog Post

What is a BRCA gene?
BRCA1 and BRCA2 are human genes involved with cell growth, cell division, and cell repair. Although they are most commonly associated with BReast CAncer, approximately 15% of women with ovarian cancer also have BRCA gene mutations.1,2

Who should get tested for the BRCA gene?
Clinical practice guidelines recommend that all women with epithelial ovarian cancer be considered for BRCA testing3. The test is simple and easy. A blood or saliva sample can be taken at your physician’s office or at a local lab. Medicare, Medicaid, and most private insurance carriers cover BRCA testing for women with a diagnosis of ovarian cancer. Certain mutations in BRCA1 or BRCA2 can affect how you and your physician choose to manage ovarian cancer.

Important BRCA Facts:

How You and Your Blog Readers Can Help

Images for Your Blog Post
Please feel free to use the images below in your blog post, and share them on your social media channels to inspire others to #beBRCAware. Click for full size images.


Submit Your Blog Post
Share your blog link with us by clicking the "submit your blog" button below and adding your blog post URL. Payment will be sent within three business days of completing the assignment and submitting your post.

 

submit your blog

References:
1. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807-2816.

2. National Cancer Institute. BRCA1 and BRCA2: Cancer risk and genetic testing. http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA. Accessed June 2, 2014.

3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 4;2013.2 

4. National Cancer Institute. BRCA1 and BRCA 2: Cancer risk and genetic testing. http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA. Last Accessed: October 30, 2014.

5. Petrucelli N, et al.,1998 Sep 4 [Updated 2013 Sep 26]. In: Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.

6. Wang ZC, et al. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res. 2012;18:5806-5815.

7. Song H., The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Human Molecular Genetics 2014;23(17):4703-4709.